Company Profile

Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company's portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson's disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer's type.

Employees

138

Sector

Biotechnology & Medical Research

More about the company

21-11-24	Adamas Pharmaceuticals, Inc. Announces Management Changes	CI
21-11-24	Adamas Pharmaceuticals, Inc.(NasdaqGM:ADMS) dropped from NASDAQ Composite Index	CI
21-11-24	Adamas Pharmaceuticals, Inc.(NasdaqGM:ADMS) dropped from S&P TMI Index	CI
21-11-24	Adamas Pharmaceuticals, Inc.(NasdaqGM:ADMS) dropped from S&P Global BMI Index	CI
21-11-23	Supernus Pharmaceuticals, Inc. completed the acquisition of Adamas Pharmaceuticals, Inc. from Mohr Davidow Ventures and others.	CI
21-11-17	Northland Downgrades Adamas Pharmaceuticals to Market Perform From Outperform; Price Target is $8.50	MT
21-11-10	Adamas Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
21-10-12	ADAMAS PHARMACEUTICALS : SVB Leerink Downgrades Adamas Pharmaceuticals to Market perform From Outperform, Adjusts Price Target to $8 From $6	MT
21-10-12	ADAMAS PHARMACEUTICALS : JMP Securities Downgrades Adamas Pharmaceuticals to Market Perform from Market Outperform	MT
21-10-12	ADAMAS PHARMACEUTICALS : Piper Sandler Downgrades Adamas Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $8 from $7	MT
21-10-12	ADAMAS PHARMACEUTICALS : HC Wainwright Downgrades Adamas Pharmaceuticals to Neutral From Buy, Trims Price Target to $9.10 From $10	MT
21-10-11	DJ Industrial : US Stocks Drop Monday as Markets Await Big Bank Earnings; Oil Price Advances	MT
21-10-11	Close Update: US Stocks Reverse Earlier Gains as Markets Await Big Bank Earnings; Oil Price Advances	MT

21-11-17	Northland Downgrades Adamas Pharmaceuticals to Market Perform From Outperform; Price Target is $8.50	MT
21-10-12	ADAMAS PHARMACEUTICALS : SVB Leerink Downgrades Adamas Pharmaceuticals to Market perform From Outperform, Adjusts Price Target to $8 From $6	MT
21-10-12	ADAMAS PHARMACEUTICALS : JMP Securities Downgrades Adamas Pharmaceuticals to Market Perform from Market Outperform	MT
21-10-12	ADAMAS PHARMACEUTICALS : Piper Sandler Downgrades Adamas Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $8 from $7	MT
21-10-12	ADAMAS PHARMACEUTICALS : HC Wainwright Downgrades Adamas Pharmaceuticals to Neutral From Buy, Trims Price Target to $9.10 From $10	MT

21-11-24	Adamas Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K	PU
21-11-24	ADAMAS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
21-11-23	Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer	AQ
21-11-11	Adamas: Q3 Earnings Snapshot	AQ
21-11-10	ADAMAS PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

15-12-23	Adamas Pharmaceuticals : Les valeurs à suivre sur les marchés américains
15-12-23	USA-Les valeurs à suivre à Wall Street
15-12-23	USA-Les valeurs à suivre à Wall Street

Director	Title	Age	Since
Bryan A. Roecklein BRD	Director/Board Member	-	2021-11-23
Jack Khattar BRD	Director/Board Member	64	2021-11-23

Adamas Pharmaceuticals, Inc. Stock

Stocks

ADMS

US00548A1060

Biotechnology & Medical Research

Latest news : Adamas Pharmaceuticals, Inc.

Analysts' recommendations: Adamas Pharmaceuticals, Inc.

Press Releases: Adamas Pharmaceuticals, Inc.

News in other languages: Adamas Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Adamas Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
21-11-23	Neil McFarlane	Free	Chief Executive Officer; Director	1,125,000	2.4622%
21-11-23	John MacPhee	Tender	Director	256,000	0.5603%
21-11-23	David Mahoney	Tender	Chairman	187,781	0.4110%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADAMAS PHARMACEUTICALS, INC.	+0.74%	+0.24%	-	-	376M
LONZA GROUP AG	+0.36%	+6.85%	+0.11%	+5.85%	48.62B
REVOLUTION MEDICINES, INC.	+0.92%	+6.21%	+408.85%	+605.33%	39.86B
IQVIA HOLDINGS INC.	+1.89%	+11.06%	+25.75%	-6.35%	33.91B
BEONE MEDICINES AG	+2.38%	+8.10%	+21.83%	+64.58%	32.32B
CELLTRION, INC.	+1.20%	+2.26%	+15.60%	+32.43%	24.73B
ASCENDIS PHARMA A/S	+2.51%	+4.94%	-	-	16.63B
MEDPACE HOLDINGS, INC.	+2.58%	+7.24%	+71.03%	+133.27%	15.52B
EUROFINS SCIENTIFIC SE	+0.99%	+3.16%	+13.75%	+18.88%	13.63B
ICON PUBLIC LIMITED COMPANY	-1.14%	+7.52%	+14.75%	-28.79%	13.41B
Average	+1.03%	+7.68%	+71.46%	+103.15%	26.52B
Weighted average by Cap.	+0.95%	+7.73%	+88.98%	+130.76%